Free Trial

RODMAN&RENSHAW Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at RODMAN&RENSHAW. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by RODMAN&RENSHAW.

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
Telomir Pharmaceuticals stock logo
TELO
Telomir Pharmaceuticals
$4.34
-4.2%
2/20/2025Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyHighView details for RODMAN&RENSHAW rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/20/2025
Talphera stock logo
TLPH
Talphera
$0.64
+0.7%
1/28/2025Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyMediumView details for RODMAN&RENSHAW rating of Talphera (NASDAQ:TLPH) on 1/28/2025
PolyPid stock logo
PYPD
PolyPid
$2.80
-5.7%
1/28/2025Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyHighView details for RODMAN&RENSHAW rating of PolyPid (NASDAQ:PYPD) on 1/28/2025
INmune Bio stock logo
INMB
INmune Bio
$8.86
+6.7%
1/28/2025Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyHighView details for RODMAN&RENSHAW rating of INmune Bio (NASDAQ:INMB) on 1/28/2025
Indivior stock logo
INDV
Indivior
$9.58
-5.1%
1/28/2025Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyLowView details for RODMAN&RENSHAW rating of Indivior (NASDAQ:INDV) on 1/28/2025
Cardiol Therapeutics stock logo
CRDL
Cardiol Therapeutics
$1.06
-5.4%
1/28/2025Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyLowView details for RODMAN&RENSHAW rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025
Atara Biotherapeutics stock logo
ATRA
Atara Biotherapeutics
$6.92
-0.3%
1/21/2025Downgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-Buy -> HoldMediumView details for RODMAN&RENSHAW rating of Atara Biotherapeutics (NASDAQ:ATRA) on 1/21/2025
Atara Biotherapeutics stock logo
ATRA
Atara Biotherapeutics
$6.92
-0.3%
12/20/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyN/AView details for RODMAN&RENSHAW rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
$3.64
+1.4%
12/19/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyN/AView details for RODMAN&RENSHAW rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024
Rockwell Medical stock logo
RMTI
Rockwell Medical
$1.20
-4.8%
11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024
Omeros stock logo
OMER
Omeros
$9.16
+1.6%
11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Omeros (NASDAQ:OMER) on 11/14/2024
Eupraxia Pharmaceuticals stock logo
EPRX
Eupraxia Pharmaceuticals
$3.54
-2.7%
11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024
Achieve Life Sciences stock logo
ACHV
Achieve Life Sciences
$2.86
-3.7%
11/14/2024Upgraded byRODMAN&RENSHAWAnalyst B. FolkesStrong-BuyN/AView details for RODMAN&RENSHAW rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024
Bicara Therapeutics stock logo
BCAX
Bicara Therapeutics
$13.03
-5.6%
11/5/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyLowView details for RODMAN&RENSHAW rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024
Quince Therapeutics stock logo
QNCX
Quince Therapeutics
$1.37
-2.1%
10/29/2024Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyHighView details for RODMAN&RENSHAW rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024
Alto Neuroscience stock logo
ANRO
Alto Neuroscience
$2.56
-3.4%
10/23/2024Downgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-Buy -> HoldMediumView details for RODMAN&RENSHAW rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024
Nkarta stock logo
NKTX
Nkarta
$1.43
-7.7%
10/9/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyHighView details for RODMAN&RENSHAW rating of Nkarta (NASDAQ:NKTX) on 10/9/2024
Kyverna Therapeutics stock logo
KYTX
Kyverna Therapeutics
$2.30
-2.1%
10/9/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyHighView details for RODMAN&RENSHAW rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024
MIRA Pharmaceuticals stock logo
MIRA
MIRA Pharmaceuticals
$1.22
-0.8%
9/30/2024Upgraded byRODMAN&RENSHAWAnalyst E. PirosStrong-BuyLowView details for RODMAN&RENSHAW rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024
Biomea Fusion stock logo
BMEA
Biomea Fusion
$2.69
-3.6%
9/26/2024Upgraded byRODMAN&RENSHAWAnalyst T. ButlerStrong-BuyLowView details for RODMAN&RENSHAW rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024

MarketBeat Community Rating for RODMAN&RENSHAW

Community Ranking:  2.5 out of 5 (
2.5 of 5 stars)
Outperform Votes:  14,085 (Vote Outperform)
Underperform Votes:  14,354 (Vote Underperform)
Total Votes:  28,439
MarketBeat's community ratings are surveys of what our community members think about RODMAN&RENSHAW and other research firms. Vote "Outperform" if you believe RODMAN&RENSHAW's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RODMAN&RENSHAW's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.